

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Meihao Medical Group Co., Ltd**

**美皓醫療集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1947)**

**SUPPLEMENTAL ANNOUNCEMENT  
IN RELATION TO  
THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2022**

Reference is made to the announcement of Meihao Medical Group Co., Ltd. (the “**Company**”) dated 29 March 2023 in relation to the audited consolidated financial results of the Company and its subsidiaries (collectively, the “**Group**”) for the year ended 31 December 2022 (the “**Announcement**”) and the annual report of the Company for the year ended 31 December 2022 (the “**Annual Report**”). Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Announcement and the Annual Report.

Further to the information disclosed in the Announcement and the Annual Report, the Company would like to provide to its shareholders and potential investors of the Company with the following supplemental information in relation to the prepayments, other receivables and other assets of the Company as at 31 December 2022 as disclosed on page 12 of the Annual Report:

The IPO proceeds receivable from the underwriter of approximately RMB67.1 million (the “**IPO Proceeds Receivable**”) comprising the prepayments, other receivables and other assets of the Company as at 31 December 2022 represented the receivable due from the overall coordinator (the “**Overall Coordinator**”) of the global offering of the shares of the Company, which was held by the Overall Coordinator on behalf of the Company under a segregated bank account of the Overall Coordinator. The prolonged settlement of the IPO Proceeds Receivable by the Overall Coordinator with the Company was primarily due to the additional time required for the approval and administration procedures to confirm the final amount of the net proceeds to be remitted by the Overall Coordinator to the Company as a result of the public holidays in Hong Kong and the impediments caused by the spread of COVID-19 in the workplaces, and the IPO Proceeds Receivable was subsequently settled by the Overall Coordinator on 12 January 2023.

The information contained in this supplemental announcement does not affect other information contained in the Announcement and Annual Report. Save as disclosed above, all other information in the Announcement and Annual Report remains unchanged.

By order of the Board  
**Meihao Medical Group Co., Ltd**  
**Mr. Wang Xiaomin**  
*Chairman and executive Director*

Hong Kong, 5 May 2023

*As at the date of this announcement, the executive Directors are Mr. Wang Xiaomin and Ms. Zheng Man, and the independent non-executive Directors are Mr. Ng Ming Chee, Ms. Tam Hon Shan Celia and Dr. Zhou Jian.*